Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over
Authors not listed
Pusan National University Hospital · 2012
Abstract
This is Phase II prospective trial of addition of rituximab to reduced dose CHOP chemotherapy in DLBC L patients aged 65 years and over.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-19 MST
Cite this
APA
Anonymous. (2012). Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over. <em>Pusan National University Hospital</em>. https://clinicaltrials.gov/study/NCT02792491
Vancouver
Anonymous. Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over. Pusan National University Hospital. 2012.
BibTeX
@misc{anon2012PhaseI,
title = {Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over},
author = {Anonymous},
journal = {Pusan National University Hospital},
year = {2012},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cancer Research Campaign Clinical Trials Centre 1992
Open access · US-GOV
A RANDOMIZED PROSPECTIVE TRIAL OF CHOP VERSUS MCOP IN ELDERLY PATIENTS WITH INTERMEDIATE AND HIGH GRADE NON-HODGKIN'S LYMPHOMA (AGED 65 YEARS AND OVER)
Lymphoma Study Association 2003
Open access · US-GOV
Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1.
Goethe University 2012
Open access · US-GOV
An Open Label Phase II Study to Evaluate the Efficacy and Safety of Induction and Consolidation Therapy With Nilotinib in Combination With Chemotherapy in Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL)
Nature Medicine 2018
Preprint · OA
Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury
SWOG Cancer Research Network 2001
Open access · US-GOV
Protocol for Assessment of Gemcitabine and Paclitaxel for Metastatic Urothelial Cancer in Patients Aged 70 Years or Older (and in a Cohort of Patients Younger Than 60 Years)
Prof. Dr. Clemens Schmitt 2017
Open access · US-GOV